AI주식인사이트AI Stock Insight
B

종근당바이오

063160KOSPI

55.5 / 100

Reference Date: 2026-10-23

Financial Score23.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

CKDBio is a fermentation and biotechnology specialist established in 2001, operating core businesses in API, probiotics, microbiome, and botulinum toxin. Leveraging over 50 years of technical expertise and adherence to global cGMP standards, the company supplies high-value products to over 40 countries. In the botulinum toxin sector, it has secured China NMPA Phase 3 clinical approval, actively expanding its global market presence.

Number of Employees

533people

Average Salary

69.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.55Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
-2.24Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
16.37Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲0.2% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲43.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.4% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 12,690Won52-week high 22,75052-week low 12,200
1-month return3.0Point

1m -1.25% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0